How is the heart best protected in chronic dialysis patients?: Between Scylla and Charybdis: what is the appropriate role for percutaneous coronary revascularization and coronary artery bypass grafting in patients on dialysis?
How is the heart best protected in chronic dialysis patients?: Between Scylla and Charybdis: what is the appropriate role for percutaneous coronary revascularization and coronary artery bypass grafting in patients on dialysis?
复制标题
如何最好地保护慢性透析患者的心脏？：Scylla 和 Charybdis 之间：经皮冠状动脉血运重建和冠状动脉旁路移植术在透析患者中的适当作用是什么？
DOI：
10.1111/sdi.12181
复制
发表时间：
2014
影响因子：
1.6
通讯作者：
Charytan,DavidM
中科院分区：
文献类型：
--
作者：
Charytan,DavidM
文章讨论了慢性透析的心脏并发症，包括慢性肾脏疾病和透析依赖的终末期肾脏疾病，这些疾病接受冠状动脉造影术或血管重建术的可能性降低了30%至40%。报告指出，在血液透析中，包括β-受体阻滞剂、肾素-血管紧张素轴阻滞剂和他汀类药物在内的药物治疗未得到充分利用。文章还讨论了经皮冠状动脉血运重建术和冠状动脉旁路移植术在透析患者中的作用。
The article discusses the heart complications of chronic dialysis including chronic kidney disease and dialysis-dependent end-stage renal disease which are 30 to 40% less likely to undergo coronary angiography or revascularization. It notes the underutilization of medical therapies including beta-blockers, renin-angiotensin axis blockers and statins in hemodialysis. It also discusses the role of percutaneous coronary revascularization and coronary artery bypass grafting in dialysis patients.